摘要
目的探讨过氧化物酶增殖活化受体激动剂对哮喘气道重塑模型气道转化生长因子β1(TGF-β1)表达的影响。方法32只BALB/C小鼠随机分为对照组(A组)、哮喘模型组(B组)、哮喘模型地塞米松干预组(C组)、哮喘模型罗格列酮干预组(D组),每组8只。采用RT-PCR法测定肺组织TGF-β1的浓度,HE染色观察肺组织病理改变。结果C、D2组小鼠的TGF-β1表达、气道平滑肌(ASM)和上皮厚度明显低于B组差异有统计学意义(P<0.05),而高于A组差异有统计学意义(P<0.05)。C、D2组差异无统计学意义(P>0.05)。结论过氧化物酶增殖活化受体激动剂可能通过抑制TGF-β1的表达,从而抑制平滑肌增生肥大,减少胶原沉积。
Objective Investigated the role of peroxisome proliferator-activated receptorsγ（PPAR-γ） on transforming growth factor TGF-β1.Methods The BALB/C mice were divided into four groups：the control group（group A）,asthmatic model group（group B）,desamethasone inhalation group（group C） and rosiglitazone inhalation group（group D）.The RT-PCR techniques was used to detected the expression of TGF-β1,and observed the pathological changes of lung tissues by HE stanning.Results TGF-β1,thickness of epithelia and airway smooth muscle （ASM） of group C ,D decreased greatly in comparison with group B （P 〈 0.05 ）, but increased obviously in comparison with group A （P 〈 0.05 ）. There was no obvious difference in group C,D （P 〉 0.05 ）. Conclusion Peroxisome proliferator-activated receptor agonists might be inhibiting TGF-β1 , expression, thereby inhibiting proliferation of smooth muscle hypertrophy and reduced collagen deposition.
出处
《临床合理用药杂志》
2009年第23期5-7,共3页
Chinese Journal of Clinical Rational Drug Use
